MYD88 and COVID-19: Dysregulation of MyD88 results in NF-kB activation that can increase lung damage (21), thus, statins preserve MyD88 at normal levels during infection and reduce NF-kB activation and it has been proposed that the modulation of TRL-MyD88 pathway by statins may be useful to treat COVID-19.